Lyophilization Services of New England, of Bedford, New Hampshire.

BEVERLY, MA–(Marketwire – Feb 27, 2012) – Cellceutix Corporation (OTCBB:  CTIX ) (“the Company”), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat unmet medical conditions, is pleased to announce that the manufacturing of Kevetrin™, the Company’s novel cancer compound for multi-drug resistant cancers, has been completed under cGMP manufacturing conditions by Lyophilization Services of New England, of Bedford, New Hampshire. The vials will be used in Kevetrin’s upcoming Phase I clinical trial.